Tag: thromboembolism

Rivaroxaban is a selective direct factor Xa inhibitor that has been associated with improved outcomes in stable patients with chronic atherosclerotic cardiovascular disease and acute coronary syndrome. Nevertheless, its role in the treatment of patients with coronary artery disease (CAD) in addition to heart failure remains unclear. In the...
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease Alzheimer disease (AD) is characterized by the accumulation of amyloid b (Ab) and tau aggregates in the brain. The progression of AD can be monitored through imaging techniques or through the use of cerebrospinal fluid (CSF) biomarkers....
1. In this retrospective cohort study, continuous (84/7) or extended (365/0) cycle regimens of combined oral contraceptives were not linked with meaningfully higher rates of venous thromboembolism (VTE) when compared with traditional cyclic (21/7) regimens. 2. This study excluded women with elevated baseline risk of venous thromboembolism (VTE). Evidence Rating Level:...
1. The EINSTEIN CHOICE trial involved patients who had a history of venous thromboembolism (VTE) and had completed 6 to 12 months of therapeutic anticoagulation and were in equipoise regarding the need for continued anticoagulation. 2. In this population, rivaroxaban at a dose of 20 mg or 10 mg daily...
1. Based on a matched control study of elderly patients for whom anticoagulation was indicated, bleeding risk was mildly higher in patients 90 or older and the same amongst patients 80-89 years old as compared with those between ages 70-79 years old. 2. The risk of thrombosis was significantly higher...
Image: PD  1. Patients with venous thromboembolism (VTE) treated with the oral factor Xa inhibitor apixaban experienced similar outcomes to patients treated with enoxaparin and warfarin.  2. Patients treated with apixaban experienced significantly fewer adverse bleeding events.  Evidence Rating Level: 1 (Excellent)  Study Rundown: This safety and efficacy study showed that in uncomplicated patients...
Image: PD 1. PICC-related deep vein thrombosis occurs in 2.7% of PICC patients, with highest frequency in patients who are critically ill and those with cancer. 2. PICCs are associated with a higher rate of deep vein thrombosis than other central venous catheters (CVCs), with a pooled OR of 2.55. Evidence Rating...
Image: CC/L. academia 1. The RE-COVER trial demonstrates that treating acute venous thromboembolism with 6 months of dabigatran 150 mg twice daily is non-inferior to dose-adjusted warfarin to an INR of 2-3. 2. Though dabigatran therapy does not require INR monitoring, it is considerably more expensive than warfarin. Study Rundown: The RE-COVER trial...
Feb 6th - NEJM - Extended-duration rivaroxaban was superior to standard-duration enoxaparin for thromboprophylaxis, but was associated with increased bleeding risk. Image: PD 1. Standard-duration rivaroxaban had no net clinical benefit over standard-duration enoxaparin for thromboprophylaxis in acutely ill hospitalized patients. 2. Extended-duration rivaroxaban was superior to standard-duration enoxaparin for thromboprophylaxis, but...